Pain management in patients with end-stage renal disease and calciphylaxis- a survey of clinical practices among physicians

[1]  A. Gold,et al.  Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis , 2019, Journal of Nephrology.

[2]  S. Davison.  Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Kamdar,et al.  Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis. , 2019, Journal of pain and symptom management.

[4]  B. Jaber,et al.  Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis , 2018, Kidney international reports.

[5]  A. Wongrakpanich,et al.  A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly , 2018, Aging and disease.

[6]  F. Murtagh.  Palliative Care in Kidney Disease , 2018 .

[7]  J. Strand,et al.  Underreported use of palliative care and patient‐reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review , 2017, The British journal of dermatology.

[8]  B. Laird,et al.  The use of opioids in cancer patients with renal impairment—a systematic review , 2017, Supportive Care in Cancer.

[9]  R. Thadhani,et al.  A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. , 2016, Journal of the American Society of Nephrology : JASN.

[10]  R. El-Damanawi,et al.  Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease , 2015, Nephron.

[11]  F. Fend,et al.  Multi-Modal Treatment Of Calciphylaxis With Sodium-Thiosulfate, Cinacalcet And Sevelamer Including Long-Term Data , 2013, Kidney and Blood Pressure Research.

[12]  L. Schurgers,et al.  Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. Vleugels,et al.  Calciphylaxis: a systematic review of existing and emerging therapies. , 2012, Journal of the American Academy of Dermatology.

[14]  G. Kan,et al.  Calcific Uremic Arteriolopathy on Multimodal Combination Therapy: Still Unmet Goal , 2012, International journal of nephrology.

[15]  E. Zecca,et al.  Cancer pain management and palliative care. , 2012, Handbook of clinical neurology.

[16]  K. Forbes,et al.  A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project , 2011, Palliative medicine.

[17]  S. Moe,et al.  Efficacy of sodium thiosulfate for the treatment for calciphylaxis. , 2011, Clinical nephrology.

[18]  Raymond Miller,et al.  A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin , 2010, Clinical pharmacokinetics.

[19]  M. Pittelkow,et al.  Calciphylaxis: natural history, risk factor analysis, and outcome. , 2007, Journal of the American Academy of Dermatology.

[20]  M. Ashby,et al.  Symptomatic management of calciphylaxis: a case series and review of the literature. , 2006, Journal of pain and symptom management.

[21]  A. Sedman,et al.  Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function , 2003, Journal of clinical pharmacology.

[22]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[23]  A. Rich,et al.  A case of difficult pain in a patient with chronic renal failure and calciphylaxis. , 2001, Journal of pain and symptom management.

[24]  C. Green,et al.  Calciphylaxis Treated With Neurolytic Lumbar Sympathetic Block: Case Report and Review of the Literature , 1999, Regional Anesthesia & Pain Medicine.